Educational Symposium

Vascular Access: Breaking the Barriers to Innovation

November 08, 2019 | 06:45 AM - 07:45 AM

Location: Marquis Ballroom, Salon 6, Marriott Marquis

Session Description

Vascular access remains the Achilles heel of ESKD care decades after the Scribner shunt revolutionized hemodialysis delivery. The optimal vascular access is consistently functional, delivering adequate dialysis without complications, at an affordable cost. The arteriovenous (AV) fistula is plagued by a high failure-to-mature rate; in most of the world, the AV graft has a limited durability; and the central venous catheter contributes to damaged vessels, inflammation, and infection. Many investigators have limited success looking for ways to enhance fistula maturation, prevent catheter infections, and prolong graft use along with improving overall patient outcomes.

More importantly, patients with ESKD come with diseased blood vessels, variable expected life expectancies, and individual preferences. Previous guidelines have recommended AV access as the preferred access; however, the current literature argues that the AV fistula may have a role in only a select group of patients.

The ESKD community is ready for a new paradigm of innovation that disrupts our current thinking about vascular access and offers improved outcomes for our patients.

Support is provided by an educational grant from Fresenius Medical Care Renal Therapies Group.

Learning Objective(s)

  • Discuss the emerging technologies in vascular access (bioengineered human acellular vessels [HAVs]), endovascular fistula, and stent graft
  • Describe the need for implementation strategies to individualize patient care

Learning Pathway(s)

  • Dialysis

Moderator

  • Kevan Polkinghorne, MBChB, PhD

Presentations